Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ritlecitinib by Pfizer for Celiac Disease: Likelihood of Approval
Ritlecitinib is under clinical development by Pfizer and currently in Phase II for Celiac Disease. According to GlobalData, Phase II...
Rimegepant sulfate ODT by Pfizer for Abdominal Pain: Likelihood of Approval
Rimegepant sulfate ODT is under clinical development by Pfizer and currently in Phase II for Abdominal Pain. According to GlobalData,...
Rimegepant sulfate ODT by Pfizer for Irritable Bowel Syndrome: Likelihood of Approval
Rimegepant sulfate ODT is under clinical development by Pfizer and currently in Phase II for Irritable Bowel Syndrome. According to...
Utomilumab by Pfizer for Follicular Lymphoma: Likelihood of Approval
Utomilumab is under clinical development by Pfizer and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
Talazoparib by Pfizer for Bladder Cancer: Likelihood of Approval
Talazoparib is under clinical development by Pfizer and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
Crizotinib by Pfizer for Glioblastoma Multiforme (GBM): Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Axitinib by Pfizer for Cervical Cancer: Likelihood of Approval
Axitinib is under clinical development by Pfizer and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Maplirpacept by Pfizer for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Fordadistrogene Movaparvovec?
Fordadistrogene Movaparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Duchenne Muscular Dystrophy. According...
Binimetinib by Pfizer for Metastatic Colorectal Cancer: Likelihood of Approval
Binimetinib is under clinical development by Pfizer and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Bosutinib by Pfizer for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Bosutinib is under clinical development by Pfizer and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Sisunatovir hydrochloride by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Sisunatovir hydrochloride is under clinical development by Pfizer and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According...
PF-06425090 by Pfizer for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval
PF-06425090 is under clinical development by Pfizer and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease)....
PF-07261271 by Pfizer for Inflammatory Bowel Disease: Likelihood of Approval
PF-07261271 is under clinical development by Pfizer and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase...
PF-07264660 by Pfizer for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
PF-07264660 is under clinical development by Pfizer and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...
PF-07799544 by Pfizer for Metastatic Melanoma: Likelihood of Approval
PF-07799544 is under clinical development by Pfizer and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
PF-07799544 by Pfizer for Solid Tumor: Likelihood of Approval
PF-07799544 is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Pfizer's Marstacimab?
Marstacimab is a monoclonal antibody commercialized by Pfizer, with a leading Pre-Registration program in Hemophilia B (Factor IX Deficiency). According...
Risk adjusted net present value: What is the current valuation of Pfizer's Giroctocogene fitelparvovec?
Giroctocogene fitelparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...